Lung Cancer Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Canada, China, Japan, France, Germany, India, Spain, South Korea - Size and Forecast 2025-2029

Lung Cancer Therapeutics Market Size 2025-2029

The lung cancer therapeutics market size is forecast to increase by USD 12.37 billion, at a CAGR of 8.3% between 2024 and 2029.

• The market is experiencing significant growth, driven by the increasing prevalence of lung cancer and the advancement of precision medicine. Precision medicine, which involves the use of genetic information to develop targeted therapies, is revolutionizing the treatment landscape for lung cancer patients. Immunotherapy, a type of precision medicine, is gaining popularity due to its ability to boost the body's immune system to fight tumors. AbbVie Inc., a leading company, offers lung cancer therapeutics such as Teliso-V. Additionally, the advent of regenerative therapies offers new opportunities for treating lung cancer. Chemotherapy, a long-standing treatment option, continues to contribute significantly to the market, but its limitations and side effects are driving the need for alternative treatments. The market is expected to grow steadily, with a focus on developing more effective and less toxic therapies for lung cancer patients.

What will be the Size of the Market During the Forecast Period?

 Request Free Sample

• The market encompasses a range of treatment modalities, including radiation therapy, chemotherapy, surgery, targeted therapy, and immunotherapy. Unhealthy lifestyles and a lack of cancer awareness continue to fuel the high incidence and mortality rates associated with lung cancer, making it a significant global health concern. According to recent estimates, lung cancer accounts for approximately 13% of all cancer deaths worldwide. Targeted therapies and precision medicine are emerging trends in the market, driven by advances in molecular understanding of the disease. These innovative approaches aim to specifically target the genetic drivers, offering potential benefits in terms of efficacy and reduced side effects.
• Pharmaceutical companies are investing heavily in research and development initiatives to bring new lung cancer therapeutics to market. These efforts are focused on various molecule types and drug classes, including small molecules, monoclonal antibodies, and gene therapy. The market is expected to grow steadily in the coming years, driven by increasing demand for effective treatment options and advancements in medical diagnostic equipment and technology. Lung cancer therapeutics include not only traditional modalities such as chemotherapy and radiation therapy, but also newer approaches like targeted therapy and immunotherapy. Lung cancer can manifest in various forms, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), as well as less common types like lung carcinoid tumors.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

• Therapy
  • Targeted therapy
  • Immunotherapy
  • Chemotherapy
• Type
  • NSCLC
  • SCLC
• End-user
  • Hospitals and specialist clinics
  • Research institutions and academic centers
  • Other
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
    • Spain
  • Asia
    • China
    • India
    • Japan
    • South Korea
  • Rest of World (ROW)

By Therapy Insights

• The targeted therapy segment is estimated to witness significant growth during the forecast period.

Lung cancer therapeutics encompass various treatment modalities, including radiation therapy, chemotherapy, surgery, targeted therapy, and immunotherapy. The targeted therapy segment is categorized based on mutations and mechanisms of action. This growth can be attributed to the rising incidence of lung cancer, driven by unhealthy lifestyles, tobacco use, smoking, second-hand smoke, and pollution. The market is expected to expand due to the increasing awareness of cancer, advanced therapeutics, and precision medicine research initiatives. Nanomedicine and medical diagnostics are also contributing to the growth of the market. Side effects remain a concern for patients undergoing these therapies.

Get a glance at the Industry report of share of various segments Request Free Sample

The targeted therapy segment was valued at USD 9.75 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 47% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Lung cancer is a major health concern in North America, with the region holding the largest market share in the market. The high prevalence of NSCLC and SCLC, two common types of lung cancer, contributes significantly to this market growth. According to the American Cancer Society, while the incidence rate of lung cancer in the US has declined, the overall prevalence of the disease has increased due to an aging population and the continued high mortality rate. Risk factors such as unhealthy lifestyles, tobacco use, and second-hand smoke continue to fuel the disease's prevalence. In the US, approved therapeutics include radiation therapy, chemotherapy, surgery, targeted therapy, and immunotherapy.

Notable drugs include Avastin, Tarceva, Taxotere, and Gemzar. Strict regulations ensure the safety and efficacy of these treatments. The market is further driven by the rising incidence of lung cancer, which is linked to heart disease, strokes, lower respiratory infections, and diabetes. Nanomedicine and advanced therapeutics offer promising avenues for future research. Cancer awareness and medical diagnostic equipment are essential for early detection and effective treatment.

Market Dynamics

Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in the adoption of the market?

The heavy contribution of immunomodulators is the key driver of the market.

• The market has experienced notable expansion due to the increasing approval of immunomodulators, specifically PD-1 and PD-L1 inhibitors, for treating the disease indications such as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Four PD-1 and PD-L1 inhibitors have been approved for lung cancer treatments. These drugs exhibit superior progression-free survival (PFS), overall survival rate (OSR), and objective response rate (ORR) in patients with NSCLC and other cancer types compared to conventional chemotherapy drugs. Unhealthy lifestyles, including tobacco use, smoking, and second-hand smoke, contribute to the high incidence rate.
• Other factors, such as rising pollution levels, heart disease, strokes, lower respiratory infections, and diabetes, also increase the risk. Targeted therapies, precision medicine, and nanomedicine are emerging areas in therapeutics. Side effects are a concern with current therapies, including radiation therapy, chemotherapy, surgery, and immunotherapy. Biomarkers and RD initiatives are crucial in the development of advanced therapeutics. Companies like Astellas are focusing on developing Molecule Type and Drug Class for various treatment types and therapy types, including genes and epithelial cells. Strict regulations ensure the safety and efficacy of these therapies. Leading players are exploring innovative approaches, such as immunotherapy and biomarkers, in therapeutics.

What is shaping the Lung Cancer Therapeutics Industry?

The advent of regenerative therapies is the upcoming market trend.

• The market is witnessing advancements in technology to provide more effective treatment options for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). Currently, chemotherapy, immunomodulators, and other biological drugs dominate the market for treating these indications. Targeted therapies, such as immunomodulators, show promising results in lung cancer treatment. However, their use does not guarantee a cure. To combat the rising incidence rate of the disease, companies are investing in research and development of regenerative therapies, including gene therapies. These targeted agents focus on specific genetic abnormalities that cause NSCLC, contributing to the treatment of the disease.
• Unhealthy lifestyles, tobacco use, second-hand smoke, and rising pollution levels are significant factors contributing to the high incidence rate of the disease. Side effects from current treatments, such as Avastin, Tarceva, Taxotere, and Gemzar, necessitate the need for advanced therapeutics. The American Cancer Society reports that the diseaseis the leading cause of cancer deaths. Nanomedicine and precision medicine are emerging areas of focus in therapeutics. Awareness regarding cancer and the availability of medical diagnostic equipment are also crucial factors influencing the market. Biomarkers play a significant role in the diagnosis and treatment.

What challenges does the Lung Cancer Therapeutics Industry face during its growth?

Adherence to available alternatives is a key challenge affecting the industry growth.

• Lung cancer, caused primarily by unhealthy lifestyles, tobacco use, and second-hand smoke, is a leading cause of deaths worldwide. The American Cancer Society reports a high incidence rate, with epithelial cells in the lungs being the most common type. While surgery and radiation therapy are preferred treatment options during the early stages due to their effectiveness and cost savings, therapeutics such as chemotherapy, targeted therapy, and immunotherapy play a crucial role in managing advanced stages and specific types of the disease. Chemotherapy drugs like Tarceva, Taxotere, and Gemzar target fast-growing cells, while targeted therapies such as Avastin and Molecule Type A from Astellas inhibit specific genes.
• Immunotherapy harnesses the body's immune system to fight cancer cells. Side effects from these therapies can be severe, necessitating the development of advanced therapeutics like nanomedicine and precision medicine. Rising pollution levels contribute to the disease, increasing the need for cancer awareness and early detection through medical diagnostic equipment. The high death rate from the disease underscores the importance of continued research and RD initiatives to develop more effective therapies. Biomarkers play a critical role in diagnosing and treating lung cancer, with genes being a significant focus. Side effects from therapeutics can limit their use, making it essential to balance their benefits with potential risks.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

AbbVie Inc. - The company offers lung cancer therapeutics such as Teliso-V.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Daiichi Sankyo Co. Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Galecto Inc.
• GlaxoSmithKline Plc
• IOVANCE Biotherapeutics Inc.
• Johnson and Johnson Services Inc.
• Merck and Co. Inc.
• Moderna Inc.
• Novartis AG
• Parexel International Corp.
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Lung cancer is a significant global health concern, with epithelial cells in the lungs being particularly susceptible to various carcinogens. Unhealthy lifestyles, including tobacco use and exposure to second-hand smoke, are leading contributors to the high incidence rate of this disease. Other risk factors, such as rising pollution levels, heart disease, strokes, lower respiratory infections, and diabetes, also increase the likelihood of developing the disease. The therapeutic landscape for such cancer is diverse, encompassing various treatment types. Traditional modalities, such as surgery, radiation therapy, and chemotherapy, have been the mainstay of treatment for decades. Radiation therapy utilizes ionizing radiation to destroy cancer cells, while surgery involves the surgical removal of the affected lung tissue.

Further, chemotherapy employs drugs to target rapidly dividing cells, including cancer cells. More recently, targeted therapies and immunotherapies have emerged as promising alternatives. Targeted therapies focus on specific genes or molecular types, inhibiting the growth and spread of cancer cells. Immunotherapies, on the other hand, harness the power of the immune system to recognize and attack cancer cells. The market is witnessing a rise in innovation, with advanced therapeutics, such as nanomedicine, gaining traction. Nanomedicine involves the use of nanoparticles to deliver drugs and other therapeutic agents directly to cancer cells, minimizing side effects and increasing efficacy.

Despite these advancements, such cancer remains a leading cause of deaths worldwide. Awareness regarding cancer and early detection are crucial in improving outcomes. Medical diagnostic equipment plays a vital role in the early detection and diagnosis of such cancer, enabling timely intervention and treatment. Stringent regulations ensure the safety and efficacy of therapeutics in the market. The drug class of monoclonal antibodies, including Avastin, Tarceva, Taxotere, and Gemzar, have shown promising results in the treatment. The therapy types and their mechanisms of action continue to evolve, with precision medicine and personalized treatment plans becoming increasingly common.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2025 and 2029
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the market growth of industry companies

We can help! Our analysts can customize this market research report to meet your requirements.Get in touch